Financhill
Back

X4 Pharmaceuticals Quote, Financials, Valuation and Earnings

X4 Pharmaceuticals Price Quote

$0.37
+0.03 (+8.7%)
(Updated: November 21, 2024 at 5:55 PM ET)

X4 Pharmaceuticals Key Stats

Sell
29
X4 Pharmaceuticals (XFOR) is a Sell

Day range:
$0.31 - $0.36
52-week range:
$0.26 - $1.60
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
1.06%

Volume:
3.2M
Avg. volume:
4M
1-year change:
-57.41%
Market cap:
$63.1M
Revenue:
$0
EPS:
$-0.08

How Much Does X4 Pharmaceuticals Make?

Data Unavailable

Is X4 Pharmaceuticals Growing As A Company?

Data Unavailable

X4 Pharmaceuticals Stock Price Performance

What Is X4 Pharmaceuticals 52-Week High & Low?

X4 Pharmaceuticals Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy X4 Pharmaceuticals?

Is X4 Pharmaceuticals Cash Flow Positive?

  • What Is XFOR Cash Flow From Operations?
    Cash flow from operations (TTM) is -$125.7M
  • What Is X4 Pharmaceuticals’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $20.3M
  • What Is X4 Pharmaceuticals’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $70.8M

X4 Pharmaceuticals Return On Invested Capital

  • Is Management Doing A Good Job?
    XFOR return on invested capital is -14.26%
  • What Is X4 Pharmaceuticals Return On Assets?
    ROA measures how assets are converting to revenues and is -10.2%
  • What Is XFOR Return On Equity?
    ROE is a measure of profitability and is -30.6%

X4 Pharmaceuticals Earnings Date & Stock Price

X4 Pharmaceuticals Competitors

X4 Pharmaceuticals Dividend Yield

X4 Pharmaceuticals Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -4.65%
Revenue: 0% -66.79%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 3.05
Upside from Last Price: 795.51%

Major Shareholders

  • How many XFOR shares are owned by institutional investors?
    152.5M XFOR shares are owned by institutional investors
  • How many XFOR shares are owned by insiders?
    4.1M XFOR shares are owned by insiders